In this issue, guest editors bring their considerable expertise to this important topic.
Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. Preface - p. xi 8. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors - p. 529 9. Renoprotective Effects of SGLT2 Inhibitors - p. 539 10. SGLT2 Inhibitors in Type 2 Diabetes Mellitus - p. 551 11. SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection - p. 561 12. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction - p. 579 13. SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits - p. 587 14. Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events - p. 597 15. SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature - p. 609 16. Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease - p. 625 17. SGLT2 Inhibitors and Safety in Older Patients - p. 635 18. Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk - p. 645
In this issue, guest editors bring their considerable expertise to this important topic.
Provides in-depth reviews on the latest updates in the field, providing actionable insights for clinical practice. Presents the latest information on this timely, focused topic under the leadership of experienced editors in the field. Authors synthesize and distill the latest research and practice guidelines to create these timely topic-based reviews.
1. Cover image - p. i 2. Title page - p. i 3. Table of Contents - p. i 4. Copyright - p. ii 5. Contributors - p. iii 6. Forthcoming Issues - p. x 7. Preface - p. xi 8. Glucose-Lowering and Metabolic Effects of SGLT2 Inhibitors - p. 529 9. Renoprotective Effects of SGLT2 Inhibitors - p. 539 10. SGLT2 Inhibitors in Type 2 Diabetes Mellitus - p. 551 11. SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: A Paradigm Shift Toward Dual Cardio-Renal Protection - p. 561 12. SGLT2 Inhibitors and Heart Failure with Preserved Ejection Fraction - p. 579 13. SGLT2 Inhibitors in Heart Failure: Early Initiation to Achieve Rapid Clinical Benefits - p. 587 14. Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events - p. 597 15. SGLT2 Inhibitors and Peripheral Vascular Events: A Review of the Literature - p. 609 16. Sodium-glucose Cotransporter 2 Inhibitors and Nonalcoholic Fatty Liver Disease - p. 625 17. SGLT2 Inhibitors and Safety in Older Patients - p. 635 18. Sodium Glucose Cotransporter 2 Inhibitors, Amputation Risk, and Fracture Risk - p. 645
